Effect of atorvastatin on vascular endothelial function and prognosis of patients with coronary heart disease after percutaneous coronary intervention

Abstract

Objective To study the effect of atorvastatin on vascular endothelial function and prognosis in patients with coronary heart disease after percutaneous coronary intervention (PCI). Methods 92 cases with coronary heart disease treated by PCI in our hospital from January 2013 to January 2015 were selected.They were divided into the control group(n=46) and the observation group (n=46) by random number table method.The control group was orally given simvastatin, and the observation group was orally given atorvastatin.The levels of ET-1, VWF, NO and CRP were measured in preoperation, postoperative 1 day and postoperative 30 days.Over 1 year follow-up and the incidence of cardiovascular events and restenosis after PCI were recorded. Results In the experimental group and the control group, the VWF, ET-1 levels before operation and 30 days after operation were lower than postoperative 1 day(t=57.797, 53.747, all P<0.001; t=4.248, 24.541, all P<0.001).30 days after the operation, the levels of NO in the observation group and the control group were higher than 1 day after the operation(t=15.407, 2.333, all P<0.05). The VWF, ET-1 levels of the observation group 30 days after the operation were lower than the control group, the level of NO was higher than the control group(t=4.884, 8.568, 6.076, all P<0.001). The CRP level of the observation group was similar to that of the control group at 1 day after operation, there was no significant difference between the two groups (t=0.226, P=0.821). The CRP level of 30 days after operation in the observation group was (5.4±2.3)mg/L, which was lower than (10.6±4.2)mg/L of the control group (t=7.365, P<0.001). The total incidence rate of CVE in the observation group was 4.35%, which was significantly lower than 32.61% of the control group(χ2=26.558, P<0.001). The restenosis rate of the observation group was 2.17%, which was lower than 10.87% of the control group(χ2=6.663, P=0.010). Conclusion Atorvastatin can effectively improve the endothelial function of patients with coronary heart disease after PCI, reduce the incidence of cardiovascular events and restenosis, it is worthy of promoting in clinical. Key words: Atorvastatin; Coronary heart disease; Angioplasty, balloon, coronary; Endothelium; Prognosis